Robert W. Baird Cuts IQVIA (NYSE:IQV) Price Target to $210.00

IQVIA (NYSE:IQV) had its price target decreased by Robert W. Baird from $212.00 to $210.00 in a research note released on Tuesday,Benzinga reports. Robert W. Baird currently has a neutral rating on the medical research company’s stock.

Other equities research analysts have also recently issued research reports about the stock. Truist Financial dropped their price target on shares of IQVIA from $265.00 to $261.00 and set a “buy” rating on the stock in a research note on Thursday, December 12th. Deutsche Bank Aktiengesellschaft cut their target price on shares of IQVIA from $270.00 to $265.00 and set a “buy” rating for the company in a research note on Friday, November 1st. Bank of America decreased their price target on shares of IQVIA from $255.00 to $235.00 and set a “buy” rating on the stock in a research note on Friday, December 13th. Morgan Stanley cut their price objective on IQVIA from $280.00 to $265.00 and set an “overweight” rating for the company in a research note on Monday, November 4th. Finally, JPMorgan Chase & Co. lowered their price target on IQVIA from $279.00 to $240.00 and set an “overweight” rating on the stock in a research note on Tuesday, November 5th. Four investment analysts have rated the stock with a hold rating, seventeen have given a buy rating and one has given a strong buy rating to the stock. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average target price of $255.71.

IQVIA Price Performance

Shares of IQVIA stock opened at $206.06 on Tuesday. The firm has a market cap of $37.40 billion, a PE ratio of 27.04, a P/E/G ratio of 2.14 and a beta of 1.48. IQVIA has a twelve month low of $187.62 and a twelve month high of $261.73. The business has a 50-day moving average price of $199.41 and a 200 day moving average price of $221.19. The company has a quick ratio of 0.81, a current ratio of 0.81 and a debt-to-equity ratio of 1.76.

Institutional Inflows and Outflows

Large investors have recently added to or reduced their stakes in the business. FMR LLC increased its position in shares of IQVIA by 38.7% during the third quarter. FMR LLC now owns 2,887,342 shares of the medical research company’s stock valued at $684,213,000 after acquiring an additional 804,963 shares during the last quarter. B. Metzler seel. Sohn & Co. Holding AG acquired a new stake in IQVIA in the 3rd quarter valued at approximately $147,683,000. JPMorgan Chase & Co. raised its position in IQVIA by 46.2% in the third quarter. JPMorgan Chase & Co. now owns 1,845,711 shares of the medical research company’s stock valued at $437,378,000 after purchasing an additional 583,396 shares during the period. Nordea Investment Management AB lifted its stake in IQVIA by 47.4% during the fourth quarter. Nordea Investment Management AB now owns 1,405,281 shares of the medical research company’s stock worth $277,908,000 after purchasing an additional 452,029 shares in the last quarter. Finally, KBC Group NV boosted its position in shares of IQVIA by 68.5% during the fourth quarter. KBC Group NV now owns 616,299 shares of the medical research company’s stock worth $121,109,000 after buying an additional 250,458 shares during the period. 89.62% of the stock is currently owned by institutional investors and hedge funds.

About IQVIA

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.